What is William Blair’s Forecast for VKTX FY2027 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities researchers at William Blair issued their FY2027 earnings estimates for Viking Therapeutics in a research report issued on Wednesday, February 5th. William Blair analyst A. Hsieh expects that the biotechnology company will post earnings of ($2.42) per share for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.97) per share.

VKTX has been the subject of a number of other reports. B. Riley restated a “buy” rating and set a $96.00 price objective (down from $109.00) on shares of Viking Therapeutics in a research report on Friday. Raymond James upped their price target on shares of Viking Therapeutics from $122.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Thursday. Maxim Group lowered their price objective on Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating on the stock in a report on Friday. Piper Sandler reduced their target price on Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating for the company in a report on Thursday. Finally, StockNews.com raised Viking Therapeutics to a “sell” rating in a research note on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Viking Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $96.92.

Viking Therapeutics Price Performance

Shares of VKTX stock opened at $32.56 on Friday. Viking Therapeutics has a 1-year low of $25.34 and a 1-year high of $99.41. The company has a market cap of $3.63 billion, a price-to-earnings ratio of -35.01 and a beta of 0.90. The stock has a 50 day simple moving average of $40.05 and a 200-day simple moving average of $53.88.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.05). During the same period in the prior year, the business earned ($0.25) earnings per share.

Insider Activity at Viking Therapeutics

In other news, COO Marianna Mancini sold 54,215 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $42.75, for a total value of $2,317,691.25. Following the transaction, the chief operating officer now owns 374,134 shares of the company’s stock, valued at $15,994,228.50. This represents a 12.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Greg Zante sold 50,309 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $42.75, for a total value of $2,150,709.75. Following the transaction, the chief financial officer now owns 165,259 shares of the company’s stock, valued at approximately $7,064,822.25. This represents a 23.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 299,014 shares of company stock worth $12,782,849. Insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On Viking Therapeutics

Large investors have recently made changes to their positions in the stock. Blue Trust Inc. purchased a new stake in Viking Therapeutics in the third quarter valued at approximately $26,000. GAMMA Investing LLC grew its stake in shares of Viking Therapeutics by 124.6% in the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 243 shares in the last quarter. Gilliland Jeter Wealth Management LLC purchased a new stake in shares of Viking Therapeutics in the 3rd quarter valued at $32,000. Stone House Investment Management LLC lifted its stake in Viking Therapeutics by 66.7% during the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 200 shares in the last quarter. Finally, YANKCOM Partnership purchased a new position in Viking Therapeutics during the 4th quarter valued at about $33,000. 76.03% of the stock is currently owned by institutional investors and hedge funds.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.